The global GLP-1 companion foods market was valued at USD 2.90 billion in 2025. It is estimated at USD 3.60 billion in 2026 and is projected to reach USD 16.58 billion by 2036, growing at a CAGR of 16.5% over the 2026-2036 forecast period. This report assesses the market in depth, covering consumer behavior, nutrition science, product innovation, claims regulation, pricing, the value chain, and competition.
The market covers foods, drinks, and supplements made or marketed for people taking GLP-1 receptor agonists and related incretin drugs for obesity or type 2 diabetes. These drugs suppress appetite, so users need small servings that still supply enough protein, fiber, vitamins, minerals, and fluids, cause little digestive discomfort, and help protect lean muscle. The scope spans drinks, meals, snacks, dairy, fiber products, supplements, and delivered meals sold through grocery, pharmacy, online, specialty, clinic, and foodservice outlets. The market includes products labeled specifically for GLP-1 users as well as the portion of general high-protein, high-fiber, and portion-controlled products bought by GLP-1 users.
GLP-1 use is changing how people shop for food, and Cornell University researchers reported in the Journal of Marketing Research in late 2025 that GLP-1 use among Americans climbed from 5.5% of the population in October 2023 to 8.3% by July 2024, with roughly one in six households including a user. According to the same research, grocery bills in those homes fell 5.5% within six months of starting the drugs and savory snack buying dropped 11%, while yogurt and fresh produce saw small gains. Food companies have begun to respond with dedicated products, led by Nestlé, Conagra Brands, and Danone.
The main restraint is that GLP-1 users simply eat less, so even as they switch to companion products, their total food spending falls, and Walmart's CEO pointed to some margin pressure from these drugs in late 2024. Claims are tightly limited, since no official definition of a GLP-1 friendly food exists in the U.S. or Europe, the FDA's updated "healthy" claim rule was finalized in December 2024, and the EU allows only claims authorized under Regulation (EC) No 1924/2006. Many patients stop treatment early, as NYU Langone Health researchers reported in 2025 that up to 70% may quit within a year. Consumers already paying for medication are reluctant to pay premium food prices when private-label protein shakes and standard frozen meals are available. Challenges include thin clinical evidence for GLP-1-specific products, formulating foods that suit reduced appetite and sensitive digestion, the lack of common criteria for GLP-1 claims, and fast-changing drug therapy.
Opportunities include nutrition for muscle preservation, as lean mass made up about 39% of the weight lost in a DXA substudy of the STEP 1 semaglutide trial, bundling with telehealth, pharmacy, and direct-to-consumer medication programs, and international expansion as semaglutide generics widen access from 2026. Key trends include explicit GLP-1 labels and dedicated ranges, recipes rebuilt around protein and fiber, smaller servings packed with nutrients, and closer links between nutrition and obesity treatment, as providers add dietitian support and meal plans to their programs.
Product types covered include protein beverages & shakes, dairy & cultured products, frozen & prepared meals, snacks & bars, dietary supplements (multivitamins & minerals, protein powders, and electrolytes & hydration), fiber & gut health products, and meal kits & delivered meals. Protein beverages & shakes are expected to hold the largest share in 2026. Drinks are an easy way to take in protein when appetite is low, they are well tolerated in small volumes, and established ready-to-drink protein brands already have wide retail reach. Frozen & prepared meals are expected to grow at the highest CAGR during the forecast period, led by new ranges from Nestlé (Vital Pursuit) and Conagra (Healthy Choice with its GLP-1 friendly badge) that provide protein-rich meals sized for a reduced appetite.
By nutritional focus, the study covers muscle preservation, portion control, micronutrient density, hydration & electrolytes, and satiety & digestive comfort. Muscle preservation is expected to account for the largest share in 2026, reflecting widespread concern about lean mass loss during GLP-1 treatment and the clinical advice issued in 2025 to eat enough protein and do strength training. Satiety & digestive comfort is expected to grow at the highest CAGR, as users look for fiber and gentle formulations that ease constipation, nausea, and other common digestive side effects.
The positioning analysis compares explicitly GLP-1 positioned products with implicitly aligned products, meaning everyday protein-rich, fiber-rich, or smaller-portion foods that GLP-1 users also buy. Implicitly aligned products are expected to hold the larger share in 2026, since a broad range of existing high-protein and portion-controlled foods already meets the needs of GLP-1 users without special labeling. Explicitly positioned products are expected to grow at the higher CAGR, as major manufacturers launch dedicated lines and add on-pack GLP-1 messages, although growth will depend on how regulators treat such claims.
The treatment stage analysis follows users from treatment initiation through active weight loss to weight maintenance & post-discontinuation. Active weight loss is expected to account for the largest share in 2026, as this is the longest phase of reduced appetite, when users most need nutrient-dense foods to avoid deficiencies and muscle loss. Weight maintenance & post-discontinuation is expected to grow at the highest CAGR, driven by the high share of patients who stop medication and need help keeping weight off and protecting muscle after treatment ends.
Channels covered are supermarkets & hypermarkets, online & direct-to-consumer, pharmacies & drugstores, clinics & telehealth programs, specialty nutrition stores, and foodservice. Supermarkets & hypermarkets are expected to hold the largest share in 2026, as frozen meals, dairy, and protein drinks are widely sold through mass grocery stores, where retailers are also testing dedicated GLP-1 sections. Clinics & telehealth programs are expected to grow at the highest CAGR, as nutrition support is built into GLP-1 prescribing and direct-to-consumer medication services, which allows providers to recommend or bundle products with ongoing care.
End users include people taking GLP-1 drugs for obesity or for type 2 diabetes, bariatric surgery patients, and other weight management consumers. GLP-1 users for obesity are expected to account for the largest share in 2026, given the rapid growth of GLP-1 use for weight loss and the focus of most dedicated products on this group. Other weight management consumers are expected to grow at the highest CAGR, as protein-rich, portion-controlled products also appeal to people managing their weight without medication, including former GLP-1 users.
North America is expected to be the largest regional market in 2026, as it has the highest rate of GLP-1 use in the world, a large packaged food industry, and the earliest dedicated product launches. Nestlé's Vital Pursuit and Boost products, Conagra's GLP-1 friendly Healthy Choice range, and Danone's Oikos muscle-support drink all launched in the U.S., where labeling is governed by FDA rules including the updated healthy claim. In Canada, semaglutide's patent expiry in 2026 should widen access to therapy and, in turn, to companion foods. Europe holds a significant share and is home to Nestlé and Danone, while use is spreading, helped by family doctors in the U.K. prescribing tirzepatide on the NHS since mid-2025; because the EU limits claims to authorized ones, European products tend to focus on protein, fiber, and muscle messages.
Asia-Pacific is expected to grow at the highest CAGR during the forecast period, supported by rising GLP-1 use, large populations with obesity and diabetes, and lower-cost generics as semaglutide protection ends in China and India in 2026. Local formats built on dairy, soy, and rice, along with well-developed online retail in China, South Korea, and Southeast Asia, should support demand. In Latin America, Mexico and Brazil have large self-pay GLP-1 markets and generic semaglutide is expected in Brazil from 2026. The Middle East & Africa is expected to grow strongly from a smaller base, led by Gulf states with some of the highest obesity rates in the world; according to the International Diabetes Federation, some 73 million adults across the Middle East and North Africa were diabetic in 2021.
In this fragmented and still-forming market, participants range from global food and drink groups and supplement brands to diet programs, meal delivery firms, store brands, and restaurant chains. Companies compete on protein and fiber content, portion size, taste and digestive tolerability, clinical credibility, brand trust, price, and access to grocery, pharmacy, and telehealth channels. Main strategies include new dedicated ranges, GLP-1 messaging on existing items, higher-protein and higher-fiber recipes, tie-ups with telehealth and care providers, and research on nutrition during therapy, while weight management companies are combining medication programs with nutrition support.
Key companies profiled in the report include Nestlé S.A. (Switzerland), Conagra Brands, Inc. (U.S.), Danone S.A. (France), The Coca-Cola Company (fairlife) (U.S.), Abbott Laboratories (U.S.), Herbalife Ltd. (U.S.), BellRing Brands, Inc. (U.S.), Glanbia plc (Ireland), The Simply Good Foods Company (U.S.), GNC Holdings, LLC (U.S.), WW International, Inc. (U.S.), HelloFresh SE (Factor) (Germany), and Smoothie King Franchises, Inc. (U.S.).
The market covers foods, drinks, and supplements made or marketed for people taking GLP-1 receptor agonists and related incretin drugs for obesity or type 2 diabetes. These drugs suppress appetite, so users need small servings that still supply enough protein, fiber, vitamins, minerals, and fluids, cause little digestive discomfort, and help protect lean muscle. The scope spans drinks, meals, snacks, dairy, fiber products, supplements, and delivered meals sold through grocery, pharmacy, online, specialty, clinic, and foodservice outlets. The market includes products labeled specifically for GLP-1 users as well as the portion of general high-protein, high-fiber, and portion-controlled products bought by GLP-1 users.
GLP-1 use is changing how people shop for food, and Cornell University researchers reported in the Journal of Marketing Research in late 2025 that GLP-1 use among Americans climbed from 5.5% of the population in October 2023 to 8.3% by July 2024, with roughly one in six households including a user. According to the same research, grocery bills in those homes fell 5.5% within six months of starting the drugs and savory snack buying dropped 11%, while yogurt and fresh produce saw small gains. Food companies have begun to respond with dedicated products, led by Nestlé, Conagra Brands, and Danone.
Market Dynamics
The market is driven by the fast-growing number of GLP-1 users, clinical advice that stresses nutrition during therapy, and the repositioning of food portfolios by large manufacturers. According to the Epic Cosmos health records database, U.S. GLP-1 prescriptions rose from fewer than 4,600 in 2018 to more than 1.4 million in 2025, and oral options such as the Wegovy pill, launched in January 2026, together with falling drug prices, should widen the user base further. A May 2025 joint advisory from four professional bodies, including the American Society for Nutrition and The Obesity Society, warned of muscle and bone loss and nutrient gaps during GLP-1 therapy and called for adequate protein and resistance training. On the supply side, Nestlé introduced Vital Pursuit meals and a Boost drink taken before meals, Conagra added a GLP-1 friendly badge to 26 Healthy Choice items at the start of 2025, and Danone's Oikos brand released a cultured dairy drink designed to support muscle.The main restraint is that GLP-1 users simply eat less, so even as they switch to companion products, their total food spending falls, and Walmart's CEO pointed to some margin pressure from these drugs in late 2024. Claims are tightly limited, since no official definition of a GLP-1 friendly food exists in the U.S. or Europe, the FDA's updated "healthy" claim rule was finalized in December 2024, and the EU allows only claims authorized under Regulation (EC) No 1924/2006. Many patients stop treatment early, as NYU Langone Health researchers reported in 2025 that up to 70% may quit within a year. Consumers already paying for medication are reluctant to pay premium food prices when private-label protein shakes and standard frozen meals are available. Challenges include thin clinical evidence for GLP-1-specific products, formulating foods that suit reduced appetite and sensitive digestion, the lack of common criteria for GLP-1 claims, and fast-changing drug therapy.
Opportunities include nutrition for muscle preservation, as lean mass made up about 39% of the weight lost in a DXA substudy of the STEP 1 semaglutide trial, bundling with telehealth, pharmacy, and direct-to-consumer medication programs, and international expansion as semaglutide generics widen access from 2026. Key trends include explicit GLP-1 labels and dedicated ranges, recipes rebuilt around protein and fiber, smaller servings packed with nutrients, and closer links between nutrition and obesity treatment, as providers add dietitian support and meal plans to their programs.
Segment Analysis
The report analyzes the market by product type, nutritional focus, positioning, treatment stage, distribution channel, end user, and geography, helping stakeholders see which products and channels are gaining from the spread of GLP-1 therapy.Product types covered include protein beverages & shakes, dairy & cultured products, frozen & prepared meals, snacks & bars, dietary supplements (multivitamins & minerals, protein powders, and electrolytes & hydration), fiber & gut health products, and meal kits & delivered meals. Protein beverages & shakes are expected to hold the largest share in 2026. Drinks are an easy way to take in protein when appetite is low, they are well tolerated in small volumes, and established ready-to-drink protein brands already have wide retail reach. Frozen & prepared meals are expected to grow at the highest CAGR during the forecast period, led by new ranges from Nestlé (Vital Pursuit) and Conagra (Healthy Choice with its GLP-1 friendly badge) that provide protein-rich meals sized for a reduced appetite.
By nutritional focus, the study covers muscle preservation, portion control, micronutrient density, hydration & electrolytes, and satiety & digestive comfort. Muscle preservation is expected to account for the largest share in 2026, reflecting widespread concern about lean mass loss during GLP-1 treatment and the clinical advice issued in 2025 to eat enough protein and do strength training. Satiety & digestive comfort is expected to grow at the highest CAGR, as users look for fiber and gentle formulations that ease constipation, nausea, and other common digestive side effects.
The positioning analysis compares explicitly GLP-1 positioned products with implicitly aligned products, meaning everyday protein-rich, fiber-rich, or smaller-portion foods that GLP-1 users also buy. Implicitly aligned products are expected to hold the larger share in 2026, since a broad range of existing high-protein and portion-controlled foods already meets the needs of GLP-1 users without special labeling. Explicitly positioned products are expected to grow at the higher CAGR, as major manufacturers launch dedicated lines and add on-pack GLP-1 messages, although growth will depend on how regulators treat such claims.
The treatment stage analysis follows users from treatment initiation through active weight loss to weight maintenance & post-discontinuation. Active weight loss is expected to account for the largest share in 2026, as this is the longest phase of reduced appetite, when users most need nutrient-dense foods to avoid deficiencies and muscle loss. Weight maintenance & post-discontinuation is expected to grow at the highest CAGR, driven by the high share of patients who stop medication and need help keeping weight off and protecting muscle after treatment ends.
Channels covered are supermarkets & hypermarkets, online & direct-to-consumer, pharmacies & drugstores, clinics & telehealth programs, specialty nutrition stores, and foodservice. Supermarkets & hypermarkets are expected to hold the largest share in 2026, as frozen meals, dairy, and protein drinks are widely sold through mass grocery stores, where retailers are also testing dedicated GLP-1 sections. Clinics & telehealth programs are expected to grow at the highest CAGR, as nutrition support is built into GLP-1 prescribing and direct-to-consumer medication services, which allows providers to recommend or bundle products with ongoing care.
End users include people taking GLP-1 drugs for obesity or for type 2 diabetes, bariatric surgery patients, and other weight management consumers. GLP-1 users for obesity are expected to account for the largest share in 2026, given the rapid growth of GLP-1 use for weight loss and the focus of most dedicated products on this group. Other weight management consumers are expected to grow at the highest CAGR, as protein-rich, portion-controlled products also appeal to people managing their weight without medication, including former GLP-1 users.
Regional Analysis
The study covers North America, Europe, Asia-Pacific, the Middle East & Africa, and Latin America, with analysis of 22 countries, the Nordic countries, Southeast Asia, Kuwait & Qatar, and five rest-of-region groups. It considers GLP-1 adoption, disease prevalence, labeling rules, and generic drug entry.North America is expected to be the largest regional market in 2026, as it has the highest rate of GLP-1 use in the world, a large packaged food industry, and the earliest dedicated product launches. Nestlé's Vital Pursuit and Boost products, Conagra's GLP-1 friendly Healthy Choice range, and Danone's Oikos muscle-support drink all launched in the U.S., where labeling is governed by FDA rules including the updated healthy claim. In Canada, semaglutide's patent expiry in 2026 should widen access to therapy and, in turn, to companion foods. Europe holds a significant share and is home to Nestlé and Danone, while use is spreading, helped by family doctors in the U.K. prescribing tirzepatide on the NHS since mid-2025; because the EU limits claims to authorized ones, European products tend to focus on protein, fiber, and muscle messages.
Asia-Pacific is expected to grow at the highest CAGR during the forecast period, supported by rising GLP-1 use, large populations with obesity and diabetes, and lower-cost generics as semaglutide protection ends in China and India in 2026. Local formats built on dairy, soy, and rice, along with well-developed online retail in China, South Korea, and Southeast Asia, should support demand. In Latin America, Mexico and Brazil have large self-pay GLP-1 markets and generic semaglutide is expected in Brazil from 2026. The Middle East & Africa is expected to grow strongly from a smaller base, led by Gulf states with some of the highest obesity rates in the world; according to the International Diabetes Federation, some 73 million adults across the Middle East and North Africa were diabetic in 2021.
Competitive Landscape
The report includes a detailed review of the competitive landscape, covering key growth strategies, competitive benchmarking, the competitive dashboard with industry leaders, market differentiators, vanguards, and emerging companies, and 2025 market share/rank analysis. Company profiles of multinational food and beverage companies, specialized nutrition and supplement companies, and weight management, meal, and foodservice companies cover business overview, financial overview, product portfolio, strategic developments, and SWOT analysis.In this fragmented and still-forming market, participants range from global food and drink groups and supplement brands to diet programs, meal delivery firms, store brands, and restaurant chains. Companies compete on protein and fiber content, portion size, taste and digestive tolerability, clinical credibility, brand trust, price, and access to grocery, pharmacy, and telehealth channels. Main strategies include new dedicated ranges, GLP-1 messaging on existing items, higher-protein and higher-fiber recipes, tie-ups with telehealth and care providers, and research on nutrition during therapy, while weight management companies are combining medication programs with nutrition support.
Key companies profiled in the report include Nestlé S.A. (Switzerland), Conagra Brands, Inc. (U.S.), Danone S.A. (France), The Coca-Cola Company (fairlife) (U.S.), Abbott Laboratories (U.S.), Herbalife Ltd. (U.S.), BellRing Brands, Inc. (U.S.), Glanbia plc (Ireland), The Simply Good Foods Company (U.S.), GNC Holdings, LLC (U.S.), WW International, Inc. (U.S.), HelloFresh SE (Factor) (Germany), and Smoothie King Franchises, Inc. (U.S.).
How This Report Helps
- Provides reliable market size estimates and long-term forecasts for the global GLP-1 companion foods market through 2036.
- Explains how growth in GLP-1 use, clinical nutrition guidance, and food industry repositioning are shaping demand.
- Assesses the impact of lower food intake, claim regulations, treatment discontinuation, and price sensitivity on the market.
- Analyzes changes in food purchasing by GLP-1 households and the nutritional needs of users at each treatment stage.
- Identifies high-growth opportunities across product type, nutritional focus, positioning, treatment stage, distribution channel, end user, and region.
- Benchmarks food, nutrition, and weight management companies on product lines, positioning, and partnerships.
- Supports product development, reformulation, channel strategy, partnership evaluation, and market entry decisions for food and beverage companies, nutrition brands, retailers, and investors.
Key Questions Answered
- How large is the global GLP-1 companion foods market today, and how will it grow through 2036?
- How are GLP-1 medications changing household food purchasing, and which categories gain or lose?
- What are the main drivers, restraints, opportunities, challenges, and trends shaping the market?
- What nutritional needs do GLP-1 users have during initiation, active weight loss, and maintenance?
- How do labeling and health claim rules in the U.S. and EU limit GLP-1 positioning?
- Which product type, nutritional focus, positioning, distribution channel, and end user segments will grow the fastest?
- Which regions and countries offer the most attractive opportunities as GLP-1 access widens?
- Who are the leading companies in the market, and how do they compare?
- What product launches, reformulations, and partnerships are shaping competition?
Table of Contents
1. Introduction
2. Research Methodology
4. Market Overview
5. GLP-1 Companion Foods Market, by Product Type
6. GLP-1 Companion Foods Market, by Nutritional Focus
7. GLP-1 Companion Foods Market, by Positioning
8. GLP-1 Companion Foods Market, by Treatment Stage
9. GLP-1 Companion Foods Market, by Distribution Channel
10. GLP-1 Companion Foods Market, by End User
11. GLP-1 Companion Foods Market, by Geography
12. Competitive Landscape
13. Company Profiles
14. Appendix
LIST OF TABLES
LIST OF FIGURES
Companies Mentioned
- Nestlé S.A.
- Conagra Brands, Inc.
- Danone S.A.
- The Coca-Cola Company
- Abbott Laboratories
- Herbalife Ltd.
- BellRing Brands, Inc.
- Glanbia plc
- The Simply Good Foods Company
- GNC Holdings, LLC
- WW International, Inc.
- HelloFresh SE
- Smoothie King Franchises, Inc.
